YahooOctober 13, 2026 at 8:19 AM NY14 Days Ago
BioNTech stock falls after cancer trial misses key endpoint
Investing.com --BioNTech (NASDAQ: BNTX) shares fell 5% on Tuesday after the company announced that a mid-to-late-stage clinical trial for its experimental mRNA cancer drug, BNT113, missed its first major goal.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
